(3S,5s,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(n-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (3S,5s,e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(n-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid
• 英文别名: (E,3S,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
• 化学式: C₂₂H₂₈FN₃O₆S
• 分子量: 481.5
• InChiKey: BPRHUIZQVSMCRT-ZUQFGZKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• pharmaceutical compositions containing crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
  申请人：AstraZeneca AB

  公开号：EP1873148A1

  公开（公告）日：2008-01-02

  The invention relates to crystalline salts of the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid, as well as processes for their manufacture, pharmaceutical compositions containing them, and their uses.

  本发明涉及化合物(E)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰)氨基]嘧啶-5-基]-(3R,5S)-3,5-二羟基庚-6-烯酸的结晶盐及其制造工艺、含有它们的药物组合物和用途。
• Processes for preparing calcium salt forms of statins
  申请人：——

  公开号：US20040176615A1

  公开（公告）日：2004-09-09

  Processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected statin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide.

  本发明提供了利用氢氧化钙从他汀类药物的酯衍生物或受保护酯衍生物制备他汀类药物钙盐的工艺。将酯或受保护酯衍生物与氢氧化钙接触以获得钙盐。首选的他汀类药物是罗伐他汀、匹伐他汀和阿托伐他汀、辛伐他汀和洛伐他汀。在从受保护的他汀酯衍生物开始的工艺中，保护基团在成盐过程中通过与氢氧化钙接触而水解，或与酸催化剂接触后再与氢氧化钙接触。
• CRYSTALLINE SALTS OF 7-¬4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-¬METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL -(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID
  申请人：AstraZeneca AB

  公开号：EP1263739B9

  公开（公告）日：2008-10-29
• 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS
  申请人：AstraZeneca AB

  公开号：EP1263747B1

  公开（公告）日：2004-11-24
• 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA
  申请人：AstraZeneca AB

  公开号：EP1458677B1

  公开（公告）日：2009-04-15